AR113754A1 - Forma cristalina de hidrato de lorlatinib base libre - Google Patents

Forma cristalina de hidrato de lorlatinib base libre

Info

Publication number
AR113754A1
AR113754A1 ARP180102913A ARP180102913A AR113754A1 AR 113754 A1 AR113754 A1 AR 113754A1 AR P180102913 A ARP180102913 A AR P180102913A AR P180102913 A ARP180102913 A AR P180102913A AR 113754 A1 AR113754 A1 AR 113754A1
Authority
AR
Argentina
Prior art keywords
lorlatinib
free base
crystal form
hydrate free
hydrate
Prior art date
Application number
ARP180102913A
Other languages
English (en)
Inventor
Peter Robert Rose
Paul Bowles
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR113754A1 publication Critical patent/AR113754A1/es

Links

Landscapes

  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una forma cristalina de hidrato de (10R)-7-amino-12-fluoro-2,10,16-trimetil-15-oxo-10,15,16,17-tetrahidro-2H-8,4-(meteno)pirazolo[4,3-h][2,5,11]benzoxadiazaciclotetradecin-3-carbonitrilo (lorlatinib) base libre, con un patrón de difracción de rayos X de polvo (PXRD) caracterizada porque comprende picos a valores 2q de: 8,8, 17,6 y 18,8 º2q ± 0,2 º2q.
ARP180102913A 2017-10-10 2018-10-09 Forma cristalina de hidrato de lorlatinib base libre AR113754A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762570326P 2017-10-10 2017-10-10

Publications (1)

Publication Number Publication Date
AR113754A1 true AR113754A1 (es) 2020-06-10

Family

ID=71523222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102913A AR113754A1 (es) 2017-10-10 2018-10-09 Forma cristalina de hidrato de lorlatinib base libre

Country Status (1)

Country Link
AR (1) AR113754A1 (es)

Similar Documents

Publication Publication Date Title
PH12015501675A1 (en) Heterocyclic amides as kinase inhibitors
EP3807279A4 (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERINE
MY180083A (en) Tetrahydropyrrolothiazine compounds
WO2016011390A8 (en) Irak4 inhibiting agents
WO2015166379A3 (en) Novel polymorphic forms of vortioxetine and its pharmaceutically acceptable salts
AR103444A1 (es) Forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
TN2018000087A1 (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
WO2014152996A8 (en) Crystalline form of a beta-lactamase inhibitor
CR20110457A (es) Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma
MX2022013274A (es) Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util.
MX2016014197A (es) 4-fenilpiperidinas sustituidas, su preparacion y uso.
WO2014153495A9 (en) Novel stat3 inhibitors
JO3318B1 (ar) مثبطات bace
EP3492468A4 (en) HETEROCYCLIC COMPOUND AS A JAK INHIBITOR, SALTS AND THERAPEUTIC USE THEREOF
ZA202200964B (en) Salts of a compound, crystal forms of the salts and preparation method and use thereof
AU2017257755A1 (en) Benzoylglycine derivatives and methods of making and using same
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
EP4335500A3 (en) Methods for the synthesis of deuterated dextromethorphan
AR113754A1 (es) Forma cristalina de hidrato de lorlatinib base libre
GB201918401D0 (en) Novel crystalline forms of Flufenacet, methods for their preparation and use of the same
AR107441A1 (es) Forma cristalina de cobicistat
HK1221225A1 (zh) -二氨基吡唑激酶抑制劑的藥學上可接受的鹽
EP4027999A4 (en) CRYSTALLINE FORM OF A MULTIPLE TYROSINE KINASE INHIBITOR, METHOD FOR PREPARATION AND USE
ES2492673T3 (es) Formas cristalinas de un ingrediente farmacéutico activo
IL272835A (en) Salts of a compound and crystalline forms thereof